\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationOnline
ProgrammesHEXA-X-II Online workshop on integrated sensing and communication towards 6G, co-organized with SNS JU
Phase 1 & 2 Projects. The event is co-organized with other SNS projects:TIMES, 6G-DISAC, Be-GREEN, TERRAMETA, 6G-SENSES, INSTINCT, ISEE-6G and 6G-MUSICAL and includes a panel session.
More info on the SNS JU website.
Hexa-X is a research initiative funded by the European Union, aimed at laying the groundwork for the next generation of wireless communication technology, commonly referred to as 6G. The project began in January 2021 and is part of the EU's Horizon 2020 program. The goal of Hexa-X is to explore and develop the foundational technologies, architectures, and use cases that will define 6G, expected to emerge around 2030.
Hexa-X-II is the successor project to Hexa-X, continuing the research and development efforts for 6G wireless communication technology.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
